外傷性脳損傷(Traumatic Brain Injury):治療薬開発パイプライン動向2018

◆英語タイトル:Traumatic Brain Injury-Pipeline Insights, 2018
◆商品コード:DIPR2016659
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年08月
◆ページ数:約60
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥137,500見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、世界における外傷性脳損傷(Traumatic Brain Injury)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の薬剤リスト等をお届けしています。また、外傷性脳損傷(Traumatic Brain Injury)治療薬開発に取り組んでいる企業情報も提供しています。

・外傷性脳損傷(Traumatic Brain Injury)の概要

・外傷性脳損傷(Traumatic Brain Injury)の治療薬パイプライン概要

・企業別開発中の外傷性脳損傷(Traumatic Brain Injury)治療薬

・後期治験段階の薬剤(Filed & Phase III):比較分析

・中期治験段階の薬剤(Phase II):比較分析

・初期治験段階の薬剤(Phase I & IND Filed):比較分析

・前臨床段階の薬剤:比較分析

・薬剤候補のプロファイル

・外傷性脳損傷(Traumatic Brain Injury)治療薬の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価

・開発が中止された薬剤リスト

・開発休止中の薬剤リスト

・外傷性脳損傷(Traumatic Brain Injury)治療薬開発に取り組んでいる企業リスト

・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “ Traumatic Brain Injury-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Traumatic Brain Injury. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Traumatic Brain Injury. DelveInsight’s Report also assesses the Traumatic Brain Injury therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitivepipeline landscape of Traumatic Brain Injury
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Traumatic Brain Injury pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Traumatic Brain Injury Overview
• Traumatic Brain Injury Pipeline Therapeutics
• Traumatic Brain Injury Therapeutics under Development by Companies
• Traumatic Brain Injury Filed and Phase III Products
• Comparative Analysis
• Traumatic Brain Injury Phase II Products
• Comparative Analysis
• Traumatic Brain Injury Phase I and IND Filed Products
• Comparative Analysis
• Traumatic Brain Injury Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Traumatic Brain Injury – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Traumatic Brain Injury – Discontinued Products
• Traumatic Brain Injury – Dormant Products
• Companies Involved in Therapeutics Development for Traumatic Brain Injury
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Traumatic Brain Injury, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Traumatic Brain Injury Assessment by Monotherapy Products
• Traumatic Brain Injury Assessment by Combination Products
• Traumatic Brain Injury Assessment by Route of Administration
• Traumatic Brain Injury Assessment by Stage and Route of Administration
• Traumatic Brain Injury Assessment by Molecule Type
• Traumatic Brain Injury Assessment by Stage and Molecule Type
• Traumatic Brain Injury Therapeutics – Discontinued Products
• Traumatic Brain Injury Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Traumatic Brain Injury, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Traumatic Brain Injury Assessment by Monotherapy Products
• Traumatic Brain Injury Assessment by Combination Products
• Traumatic Brain Injury Assessment by Route of Administration
• Traumatic Brain Injury Assessment by Stage and Route of Administration
• Traumatic Brain Injury Assessment by Molecule Type
• Traumatic Brain Injury Assessment by Stage and Molecule Type


【レポートのキーワード】

外傷性脳損傷(Traumatic Brain Injury)、治療薬、医薬品、薬剤、製薬企業、研究開発、治験、パイプライン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 外傷性脳損傷(Traumatic Brain Injury):治療薬開発パイプライン動向2018(Traumatic Brain Injury-Pipeline Insights, 2018)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆